Michael B. Jordan, MD
Appointment
Assistant Professor
Email
michael.jordan@cchmc.org
Phone
513-636-0281
Fax
513-636-5355
Credentials
MD: UT Southwestern, Dallas, TX 1993
Residency: Pediatrics, Children's Hospital of Dallas, 1996
Fellowship: The Children's Hospital (Denver) 2002
Certification: American Board of Pediatrics, 1996; Sub-board of Pediatric Heme/Onc 2002
Awards and Honors
- 2003 Nezelof Award for outstanding research into histiocytic disorders, The Histiocyte Society
Research
Better understanding histiocytic disorders and developing novel therapies for them; regulation of the immune response; immunotherapy of cancer
Research Grants and Contracts
"An Animal Model of Hemophagocytic Lymphohistiocytosis"
9/02-9/05
The Histiocytosis Association of America
Role: Principle investigator,
K08 AI50802
6/02-6/05
"B Cell Expansion After Dendritic Cell Immunization"
Role: Principle investigator
2 K12 HD28827
9/04-9/06
Pediatric Center for Gene Expression and Development
Role: Investigator
Publications, Most Recent
Connect to Michael Jordan's publications on PubMed
Hoffmann PR, Kench JA, Vondracek A, Kruk E, Daleke DL, Jordan M, Marrack P, Henson PM, Fadok VA. Interaction between Phosphatidylserine and the Phosphatidylserine Receptor Inhibits Immune Responses In Vivo.J Immunol. 2005 Feb 1;174(3):1393-404.
Jordan MB, McClain KL, Yan X, Hicks J, Jaffe R. Anti-CD52 Antibody, Alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.Pediatric Blood and Cancer, 2005 Mar;44(3):251-4.
Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder.Blood. 2004 Aug 1;104(3):735-43).
Jordan MB, Mills DM, Kappler J, Marrack P, Cambier JC. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science. 2004 Jun 18;304(5678):1808-10.
Jordan, M., van Rooijen, N., Izui, S., Kappler, J. and Marrack, P. 2003. Liposomal clodronate as a novel agent for treating autoimmune hemolytic anemia in a mouse model.Blood 101:594-601.
Kedl, R., Jordan, M., Potter, T., Kappler, J., Marrack, P. and Dow, S. 2001. CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination.Proc. Natl. Acad. Sci. 98(19):10811-6.
Professional Organization Memberships
- American Society of Hematology
- The Histiocyte Society
Special Interests
Histiocytic disorders: HLH and LCH
Related Areas
This person works in these other areas at Cincinnati Children's Hospital Medical Center:
